AgeX Therapeutics (NYSE:AGE) Stock Price Down 7.3%

AgeX Therapeutics, Inc. (NYSE:AGE – Get Rating)’s share price was down 7.3% on Monday . The company traded as low as $0.52 and last traded at $0.52. Approximately 92,505 shares changed hands during trading, an increase of 351% from the average daily volume of 20,491 shares. The stock had previously closed at $0.56.

AgeX Therapeutics Price Performance

The company has a market cap of $19.74 million, a P/E ratio of -1.79 and a beta of 1.50. The stock’s 50-day moving average is $0.61 and its two-hundred day moving average is $0.62.

AgeX Therapeutics (NYSE:AGE – Get Rating) last issued its quarterly earnings data on Friday, March 31st. The company reported ($0.07) earnings per share for the quarter. The company had revenue of $0.01 million for the quarter.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Sigma Planning Corp raised its position in AgeX Therapeutics by 15.2% in the fourth quarter. Sigma Planning Corp now owns 134,977 shares of the company’s stock worth $74,000 after acquiring an additional 17,777 shares during the period. Creative Planning raised its position in shares of AgeX Therapeutics by 38.2% during the 2nd quarter. Creative Planning now owns 72,360 shares of the company’s stock valued at $42,000 after purchasing an additional 20,000 shares during the period. Finally, Susquehanna International Group LLP bought a new stake in shares of AgeX Therapeutics during the 4th quarter valued at $29,000. 12.51% of the stock is currently owned by institutional investors.

About AgeX Therapeutics

(Get Rating)

AgeX Therapeutics, Inc operates as a biotechnology company, which engages in the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. Its product pipeline includes AGEX-VASC1, AGEX-BAT1, and AGEX-iTR1547. The company was founded by Michael D. West in 2017 and is headquartered in Alameda, CA.